ALEXANDRIA, Va., July 16 -- United States Patent no. 12,668,643, issued on June 30, was assigned to Ramot at Tel-Aviv University Ltd. (Tel-Aviv, Israel).
"Modular platform for targeted therapeutics" was invented by Ranit Kedmi (Tel-Aviv, Israel), Nuphar Veiga (Yaukum, Israel), Itai Benhar (Rehovot, Israel) and Dan Peer (Kiryat-Ono, Israel).
According to the abstract* released by the U.S. Patent & Trademark Office: "A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed."
The patent was filed on June 7, 2023, under Application No. 18/206,645.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2F...